Skip to main content
Sign In

Anschutz Medical Campus

University of Colorado Denver
​​​​​​​​​​
 

Research

The CU Anschutz Medical Campus is a nationally recognized leader in the creation of new knowledge and innovative approaches to improving human health. With sponsored research awards totaling more than $400 million annually, CU Anschutz researchers collaborate with partner and affiliate hospitals, clinics and centers to bring research from the bench to the patient’s bedside.

Innov​a​tion

The CU Anschutz tradition of innovation has created several groundbreaking achievements, including the first liver transplant in the world, the first vaccine for shingles, and the first to use human cell cloning to study genetics and cancer.

Disc​​overy

Discoveries on the Anschutz Medical Campus have led to new medical devices, pharmaceuticals, diagnostic methods, treatment of debilitating conditions and improved quality of life for patients and consumers worldwide. Since 2002, CU Anschutz technology has led to the filing of 1,300 patent applications and the formation of 53 new companies, funded by more than $914 million in venture capital and public and private equity investment and grants. ​​​​​​​​​​​​​

Research Resources

Visit Connection Points to search our researcher database and learn about our areas of expertise. Get information about our labs, facilities and clinical trials. Read about our Good Manufacturing Practice facility for cell bio-manufacturing.

Learn more

Second CU-developed vaccine for shingles approved by FDA

Microscopic view of shingles virus
The Centers for Disease Control’s Advisory Committee on Immunization Practices has recommended new treatment practices for shingles based on a vaccine initially developed at the University of Colorado Health Sciences Center, now the University of Colorado Anschutz Medical Campus. Paul Tabor, associate director of CU Innovations at the University of Colorado Anschutz, said, “The Shingrix vaccine is an important advance in the prevention of a very painful disease that affects millions of people each year and disproportionally impacts patients over 50 years old.”

Read more